Search results
Results from the WOW.Com Content Network
Mayo v. Prometheus, 566 U.S. 66 (2012), was a case decided by the Supreme Court of the United States that unanimously held that claims directed to a method of giving a drug to a patient, measuring metabolites of that drug, and with a known threshold for efficacy in mind, deciding whether to increase or decrease the dosage of the drug, were not patent-eligible subject matter.
On March 20, 2012, the United States Supreme Court ruled in Mayo Collaborative Services v. Prometheus Laboratories, Inc. [40] that a process patent, which Prometheus Laboratories had obtained for correlations between blood test results and patient health in determining an appropriate dosage of a specific medication for the patient, is not ...
Case name Citation Date decided Martinez v. Ryan: 10–1001: March 20, 2012 Coleman v. Ct. App. 10–1016: March 20, 2012 Mayo Collab. Serv. v. Prometheus ...
Bilski was followed by the Court's unanimous opinion in Mayo Collaborative Services v. Prometheus Labs, Inc. [ 15 ] Although it did not involve a software patent (it concerned a medical assay implementing a natural principle), it stated a methodology for determining patent eligibility that is currently dominant in software cases.
In Mayo v. Prometheus, the Supreme Court invalidated a patent on a diagnostic method, because it non-inventively implemented a natural principle; the Court drew on cases involving computer software and other abstract ideas. In this case, the Court was much more detailed in describing how to recognize a patent-ineligible claim to an abstract idea.
Litigation over patents covering diagnostic kits to monitor the dosing of these drugs led to a US Supreme Court case, Mayo Collaborative Services v. Prometheus Laboratories, Inc. that dramatically changed the nature of patent law in the United States. [2] [3]
Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015), [1] is a controversial decision of the US Federal Circuit in which the court applied the Mayo v. . Prometheus test [2] to invalidate on the basis of subject matter eligibility a patent said to "solve ... a very practical problem accessing fetal DNA without creating a major health risk for the unborn chil
Apple v. HTC (US, 2010) Apple Inc. v. Samsung Electronics Co., Ltd. (multiple, multinational cases, ongoing [citation needed]) Ariad v. Lilly (US, 2006) Arizona Cartridge Remanufacturers Association Inc. v. Lexmark International Inc. (US, 2005) Association for Molecular Pathology v. Myriad Genetics (US, 2013)